PART 01: EXECUTIVE SUMMARY PART 02: SCOPE OF THE REPORT PART 03: RESEARCH METHODOLOGY PART 04: MARKET LANDSCAPE • Market ecosystem • Market characteristics • Market segmentation analysis PART 05: PIPELINE ANALYSIS • Urticaria pipeline analysis PART 06: MARKET SIZING • Market definition • Market sizing 2017 • Market size and forecast 2017-2022 PART 07: FIVE FORCES ANALYSIS • Bargaining power of buyers • Bargaining power of suppliers • Threat of new entrants • Threat of substitutes • Threat of rivalry • Market condition PART 08: BY TYPE OF DRUG • Segmentation by type of drug • Antihistamines • Anti-inflammatory agents • Sulfones • Biologics PART 09: MARKET SEGMENTATION BY APPLICATION • Segmentation by application • Comparison by application • Acute urticaria – Market size and forecast 2017-2022 • Chronic urticaria – Market size and forecast 2017-2022 • Market opportunity by application PART 10: CUSTOMER LANDSCAPE PART 11: REGIONAL LANDSCAPE • Geographical segmentation • Regional comparison • EMEA – Market size and forecast 2017-2022 • Americas – Market size and forecast 2017-2022 • APAC – Market size and forecast 2017-2022 • Market opportunity PART 12: DECISION FRAMEWORK PART 13: DRIVERS AND CHALLENGES • Market drivers • Market challenges PART 14: MARKET TRENDS • Introduction of biologics for the treatment of urticaria • International guidelines for diagnosis and management of urticaria PART 15: VENDOR LANDSCAPE • Overview • Landscape disruption PART 16: VENDOR ANALYSIS • Vendors covered • Vendor classification • Market positioning of vendors • F. Hoffmann-La Roche (Genentech) • JDP Therapeutics • Meiji Holdings • Novartis • Taiho Pharmaceutical PART 17: APPENDIX • List of abbreviations PART 18: EXPLORE TECHNAVIO     Exhibit 01: Parent market Exhibit 02: Global dermatological drugs market Exhibit 03: Market characteristics Exhibit 04: Market segments Exhibit 05: Pipeline drugs for urticaria Exhibit 06: Market definition - Inclusions and exclusions checklist Exhibit 07: Market size 2017 Exhibit 08: Validation techniques employed for market sizing 2017 Exhibit 09: Global – Market size and forecast 2017-2022 ($ mn) Exhibit 10: Global – Year-over-year growth 2018-2022 (%) Exhibit 11: Five forces analysis 2017 Exhibit 12: Five forces analysis 2022 Exhibit 13: Bargaining power of buyers Exhibit 14: Bargaining power of suppliers Exhibit 15: Threat of new entrants Exhibit 16: Threat of substitutes Exhibit 17: Threat of rivalry Exhibit 18: Market condition - Five forces 2017 Exhibit 19: Application – Market share 2017-2022 (%) Exhibit 20: Comparison by application Exhibit 21: Acute urticaria – Market size and forecast 2017-2022 ($ mn) Exhibit 22: Acute urticaria – Year-over-year growth 2018-2022 (%) Exhibit 23: Chronic urticaria – Market size and forecast 2017-2022 ($ mn) Exhibit 24: Chronic urticaria – Year-over-year growth 2018-2022 (%) Exhibit 25: Market opportunity by application Exhibit 26: Customer landscape Exhibit 27: Global – Market share by geography 2017-2022 (%) 57 Exhibit 28: Regional comparison 58 Exhibit 29: EMEA – Market size and forecast 2017-2022 ($ mn) Exhibit 30: EMEA – Year-over-year growth 2018-2022 (%) Exhibit 31: Top 3 countries in EMEA Exhibit 32: Americas – Market size and forecast 2017-2022 ($ mn) Exhibit 33: Americas – Year-over-year growth 2018-2022 (%) Exhibit 34: Top 3 countries in Americas Exhibit 35: APAC – Market size and forecast 2017-2022 ($ mn) Exhibit 36: APAC – Year-over-year growth 2018-2022 (%) Exhibit 37: Top 3 countries in APAC Exhibit 38: Market opportunity Exhibit 39: Vendor landscape Exhibit 40: Landscape disruption Exhibit 41: Vendors covered Exhibit 42: Vendor classification Exhibit 43: Market positioning of vendors Exhibit 44: F. Hoffmann-La Roche (Genentech) - Overview Exhibit 45: F. Hoffmann-La Roche (Genentech) – Business segments Exhibit 46: F. Hoffmann-La Roche (Genentech) – Organizational developments Exhibit 47: F. Hoffmann-La Roche (Genentech) – Geographic focus Exhibit 48: F. Hoffmann-La Roche (Genentech) – Segment focus Exhibit 49: F. Hoffmann-La Roche (Genentech) – Key offerings Exhibit 50: JDP Therapeutics – Overview Exhibit 51: JDP Therapeutics – Business segments Exhibit 52: JDP Therapeutics – Organizational developments Exhibit 53: JDP Therapeutics – Key offerings Exhibit 54: Meiji Holdings – Overview Exhibit 55: Meiji Holdings – Organizational developments Exhibit 56: Meiji Holdings – Key offerings Exhibit 57: Novartis – Overview Exhibit 58: Novartis – Business segments Exhibit 59: Novartis – Organizational development Exhibit 60: Novartis – Geographic focus Exhibit 61: Novartis – Segment focus Exhibit 62: Novartis – Key offerings Exhibit 63: Taiho Pharmaceutical – Overview Exhibit 64: Novartis – Organizational developments Exhibit 65: Taiho pharmaceutical – Key offerings    

F. Hoffmann-La Roche (Genentech) JDP Therapeutics Meiji Holdings Novartis Taiho Pharmaceutical